Auxilium Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AUXL)

$36.47 0.00 (0.00 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$36.47
Today's RangeN/A
52-Week Range$17.10 - $37.92
VolumeN/A
Average Volume1.32 million shs
Market Capitalization$1.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.66

About Auxilium Pharmaceuticals (NASDAQ:AUXL)

Auxilium Pharmaceuticals logoAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

Receive AUXL News and Ratings via Email

Sign-up to receive the latest news and ratings for AUXL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryPharmaceuticals
SectorBiopharmaceuticals
SymbolNASDAQ:AUXL
CUSIP05334D10
Phone+1-484-3215900

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($3.27)
Net IncomeN/A
Net Margins-29.78%
Return on Equity-76.75%
Return on Assets-11.59%

Miscellaneous

EmployeesN/A
Outstanding Shares51,020,000

Auxilium Pharmaceuticals (NASDAQ:AUXL) Frequently Asked Questions

What is Auxilium Pharmaceuticals' stock symbol?

Auxilium Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUXL."

How were Auxilium Pharmaceuticals' earnings last quarter?

Auxilium Pharmaceuticals Inc (NASDAQ:AUXL) issued its earnings results on Thursday, October, 30th. The biopharmaceutical company reported $0.27 EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.30. The biopharmaceutical company earned $109.60 million during the quarter, compared to analyst estimates of $101.02 million. Auxilium Pharmaceuticals had a negative return on equity of 76.75% and a negative net margin of 29.78%. The firm's revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.17 EPS. View Auxilium Pharmaceuticals' Earnings History.

Who are some of Auxilium Pharmaceuticals' key competitors?

How do I buy Auxilium Pharmaceuticals stock?

Shares of Auxilium Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Auxilium Pharmaceuticals' stock price today?

One share of Auxilium Pharmaceuticals stock can currently be purchased for approximately $36.47.

How big of a company is Auxilium Pharmaceuticals?

Auxilium Pharmaceuticals has a market capitalization of $1.85 billion.

How can I contact Auxilium Pharmaceuticals?

Auxilium Pharmaceuticals' mailing address is 640 Lee Rd, CHESTERBROOK, PA 19087-5636, United States. The biopharmaceutical company can be reached via phone at +1-484-3215900.


MarketBeat Community Rating for Auxilium Pharmaceuticals (AUXL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  372
MarketBeat's community ratings are surveys of what our community members think about Auxilium Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Auxilium Pharmaceuticals (NASDAQ:AUXL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AHoldHold
Consensus Rating Score: N/AN/A2.002.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/A$33.25$33.25
Price Target Upside: N/AN/A8.83% downside8.83% downside

Auxilium Pharmaceuticals (NASDAQ:AUXL) Consensus Price Target History

Price Target History for Auxilium Pharmaceuticals (NASDAQ:AUXL)

Auxilium Pharmaceuticals (NASDAQ:AUXL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2016MKM PartnersDowngradeBuy -> Neutral$32.00 -> $33.25N/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Auxilium Pharmaceuticals (NASDAQ:AUXL) Earnings History and Estimates Chart

Earnings by Quarter for Auxilium Pharmaceuticals (NASDAQ:AUXL)

Auxilium Pharmaceuticals (NASDAQ AUXL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2014Q314($0.03)$0.27$101.02 million$109.60 millionViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.54)$482.80 million$83.00 millionViewListenView Earnings Details
5/5/2014Q114($0.14)($0.39)$89.20 million$8.50 millionViewListenView Earnings Details
2/28/2014Q413$0.22$0.27$111.83 million$125.90 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.03)$0.02$91.43 million$100.50 millionViewListenView Earnings Details
4/29/2013Q1 2013$0.02($0.05)$81.23 million$66.20 millionViewListenView Earnings Details
2/26/2013Q4 2012$1.72$1.83$171.20 million$172.50 millionViewListenView Earnings Details
11/7/2012Q312($0.07)($0.21)$79.54 million$71.00 millionViewN/AView Earnings Details
7/31/2012($0.05)$0.16ViewN/AView Earnings Details
5/10/2012($0.11)($0.04)ViewN/AView Earnings Details
2/23/2012($0.16)($0.25)ViewN/AView Earnings Details
10/31/2011($0.20)($0.08)ViewN/AView Earnings Details
8/1/2011($0.19)($0.11)ViewN/AView Earnings Details
5/9/2011($0.24)($0.25)ViewN/AView Earnings Details
2/10/2011($0.30)($0.34)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Auxilium Pharmaceuticals (NASDAQ:AUXL) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Auxilium Pharmaceuticals (NASDAQ:AUXL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Auxilium Pharmaceuticals (NASDAQ AUXL) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Auxilium Pharmaceuticals (NASDAQ:AUXL)

Auxilium Pharmaceuticals (NASDAQ AUXL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/5/2014Adrian AdamsCEOSell40,000$33.97$1,358,800.00View SEC Filing  
12/5/2014Paul A FriedmanDirectorSell29,689$33.73$1,001,409.97View SEC Filing  
12/3/2014Oliver FetzerDirectorSell100,000$34.02$3,402,000.00View SEC Filing  
11/25/2014James Patrick TursiInsiderSell13,713$34.12$467,887.56View SEC Filing  
11/21/2014Andrew I KovenCAOSell139,683$33.43$4,669,602.69View SEC Filing  
11/21/2014James Patrick TursiInsiderSell74,648$33.19$2,477,567.12View SEC Filing  
11/21/2014Jennifer Lou ArmstrongSVPSell75,803$33.50$2,539,400.50View SEC Filing  
3/14/2014Tito Benjamin Del, Jr.EVPSell32,032$29.50$944,944.00View SEC Filing  
3/5/2014Rolf ClassonDirectorSell10,000$31.85$318,500.00View SEC Filing  
12/13/2013Tito Benjamin Del, Jr.EVPSell4,602$20.50$94,341.00View SEC Filing  
12/11/2013James FickenscherCFOSell71,067$20.37$1,447,634.79View SEC Filing  
8/15/2013Oliver FetzerDirectorSell1,900$18.75$35,625.00View SEC Filing  
5/20/2013William MckeeDirectorSell2,000$15.10$30,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Auxilium Pharmaceuticals (NASDAQ AUXL) News Headlines

Source:
DateHeadline
Analyzing Auxilium Pharmaceuticals (AUXL) and Its CompetitorsAnalyzing Auxilium Pharmaceuticals (AUXL) and Its Competitors
www.americanbankingnews.com - December 11 at 3:34 PM
Auxilium Pharmaceuticals (AUXL) versus Its Peers Head-To-Head SurveyAuxilium Pharmaceuticals (AUXL) versus Its Peers Head-To-Head Survey
www.americanbankingnews.com - December 10 at 7:20 PM
Comparing Auxilium Pharmaceuticals (AUXL) and Its PeersComparing Auxilium Pharmaceuticals (AUXL) and Its Peers
www.americanbankingnews.com - December 8 at 8:40 AM
Comparing Auxilium Pharmaceuticals (AUXL) and Its CompetitorsComparing Auxilium Pharmaceuticals (AUXL) and Its Competitors
www.americanbankingnews.com - December 4 at 5:12 AM
Reviewing Auxilium Pharmaceuticals (AUXL) & Its CompetitorsReviewing Auxilium Pharmaceuticals (AUXL) & Its Competitors
www.americanbankingnews.com - December 3 at 9:48 PM
Analyzing Auxilium Pharmaceuticals (AUXL) & Its PeersAnalyzing Auxilium Pharmaceuticals (AUXL) & Its Peers
www.americanbankingnews.com - November 26 at 9:18 PM
Critical Analysis: Auxilium Pharmaceuticals (AUXL) versus The CompetitionCritical Analysis: Auxilium Pharmaceuticals (AUXL) versus The Competition
www.americanbankingnews.com - November 25 at 1:22 AM
Auxilium Pharmaceuticals (AUXL) versus Its Peers Critical ContrastAuxilium Pharmaceuticals (AUXL) versus Its Peers Critical Contrast
www.americanbankingnews.com - November 19 at 11:30 AM
Critical Analysis: Auxilium Pharmaceuticals (AUXL) vs. Peregrine Pharmaceuticals (PPHM)Critical Analysis: Auxilium Pharmaceuticals (AUXL) vs. Peregrine Pharmaceuticals (PPHM)
www.americanbankingnews.com - November 10 at 7:32 PM
Auxilium Pharmaceuticals (AUXL) versus KalVista Pharmaceuticals (KALV) Head to Head SurveyAuxilium Pharmaceuticals (AUXL) versus KalVista Pharmaceuticals (KALV) Head to Head Survey
www.americanbankingnews.com - October 23 at 4:32 AM
Fortress Biotech (FBIO) & Auxilium Pharmaceuticals (AUXL) Critical ComparisonFortress Biotech (FBIO) & Auxilium Pharmaceuticals (AUXL) Critical Comparison
www.americanbankingnews.com - October 20 at 8:32 AM
Auxilium Pharmaceuticals (AUXL) & Onconova Therapeutics (ONTX) Critical ComparisonAuxilium Pharmaceuticals (AUXL) & Onconova Therapeutics (ONTX) Critical Comparison
www.americanbankingnews.com - October 15 at 4:08 PM
Head-To-Head Review: Auxilium Pharmaceuticals (AUXL) versus BioMarin Pharmaceutical (BMRN)Head-To-Head Review: Auxilium Pharmaceuticals (AUXL) versus BioMarin Pharmaceutical (BMRN)
www.americanbankingnews.com - September 28 at 10:48 AM
Financial Survey: Auxilium Pharmaceuticals (AUXL) versus Alimera Sciences (ALIM)Financial Survey: Auxilium Pharmaceuticals (AUXL) versus Alimera Sciences (ALIM)
www.americanbankingnews.com - September 7 at 8:28 PM
Auxilium Pharmaceuticals (NASDAQ:AUXL) vs. Biogen (BIIB) Head to Head AnalysisAuxilium Pharmaceuticals (NASDAQ:AUXL) vs. Biogen (BIIB) Head to Head Analysis
www.americanbankingnews.com - July 24 at 8:22 PM
Endo International (ENDP) Earnings Report: Q1 2015 Conference Call TranscriptEndo International (ENDP) Earnings Report: Q1 2015 Conference Call Transcript
www.thestreet.com - May 11 at 2:46 PM
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements aAUXILIUM PHARMACEUTICALS INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements a
biz.yahoo.com - January 30 at 4:56 PM
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a MateriaAUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Materia
biz.yahoo.com - January 29 at 4:50 PM
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD DAUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD D
biz.yahoo.com - January 27 at 1:38 PM
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Other EventsAUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events
biz.yahoo.com - January 21 at 6:01 AM
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsAUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - December 22 at 11:16 AM
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal OfficersAUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - December 19 at 1:12 PM
Why Endo Wants to Acquire Auxilium So MuchWhy Endo Wants to Acquire Auxilium So Much
247wallst.com - September 17 at 10:05 AM

SEC Filings

Auxilium Pharmaceuticals (NASDAQ:AUXL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Auxilium Pharmaceuticals (NASDAQ:AUXL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Auxilium Pharmaceuticals (NASDAQ AUXL) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.